{'fraction_non_alphanumeric': 0.02784503631961259, 'fraction_numerical': 0.006053268765133172, 'mean_word_length': 5.2180451127819545, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Incretin-based therapies for type 2 diabetes: a nurse's perspective.

Type 2 diabetes (T2D) is a serious and increasing problem in the UK. Large numbers of people are suffering from the disease, and its onset is occurring at younger ages, requiring prolonged treatment. Current therapies pose challenges for patients and health professionals, and new methods of treatment are therefore needed. This article examines a group of treatments--the incretin therapies--which have recently become available. It considers the clinical evidence for these therapies relevant to UK-based prescribing, and their potential benefits for patients with T2D. Awareness of these therapies, the evidence supporting them, and the clinical recommendations for their use will allow diabetes nurses to expand treatment options for patients with T2D.